A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...
Vietnam Investment Review on MSN
Lynk Pharma reports positive phase III results for Zemprocitinib in RA
HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development ...
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), a clinical stage innovative drug development company focused on developing innovative therapies for immune and ...
Krish S. Krishnan, Chairman and Chief Executive Officer, and Suma M. Krishnan, President of Research and Development, will highlight these updates and Krystal’s strategic vision in a presentation at ...
Recent research has shown surprising health benefits of coffee, including a reduction in AFib frequency and a decrease in the ...
Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...
CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...
BIRMINGHAM, AL, UNITED STATES, January 8, 2026 / EINPresswire.com / — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback